Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Update

Assembly Biosciences, Inc. (NASDAQ:ASMB) was the recipient of a significant decline in short interest in December. As of December 15th, there was short interest totalling 13,300 shares, a decline of 16.4% from the November 30th total of 15,900 shares. Currently, 0.3% of the shares of the stock are short sold. Based on an average trading volume of 33,400 shares, the days-to-cover ratio is currently 0.4 days.

Insiders Place Their Bets

In other news, major shareholder Alexander Schornstein acquired 10,000 shares of Assembly Biosciences stock in a transaction that occurred on Tuesday, October 8th. The shares were acquired at an average price of $14.58 per share, for a total transaction of $145,800.00. Following the transaction, the insider now directly owns 703,113 shares of the company’s stock, valued at approximately $10,251,387.54. The trade was a 1.44 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders sold 394 shares of company stock valued at $5,894. 5.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Assembly Biosciences

Large investors have recently bought and sold shares of the business. Armistice Capital LLC bought a new stake in Assembly Biosciences in the second quarter valued at $6,421,000. Renaissance Technologies LLC grew its stake in shares of Assembly Biosciences by 39.2% in the 2nd quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock valued at $753,000 after buying an additional 15,451 shares during the period. Acadian Asset Management LLC increased its position in Assembly Biosciences by 131.0% in the 2nd quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 7,690 shares in the last quarter. FMR LLC raised its stake in Assembly Biosciences by 29.7% during the 3rd quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock worth $240,000 after buying an additional 3,635 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in Assembly Biosciences by 5,137.3% in the third quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 3,442 shares in the last quarter. 19.92% of the stock is currently owned by institutional investors and hedge funds.

Assembly Biosciences Trading Down 3.1 %

Shares of ASMB traded down $0.49 during trading hours on Tuesday, hitting $15.54. 15,293 shares of the stock were exchanged, compared to its average volume of 25,484. Assembly Biosciences has a fifty-two week low of $9.12 and a fifty-two week high of $19.93. The business has a 50-day moving average of $16.04 and a 200-day moving average of $15.59.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on ASMB shares. HC Wainwright reaffirmed a “neutral” rating on shares of Assembly Biosciences in a research note on Friday. Jefferies Financial Group upgraded Assembly Biosciences from a “hold” rating to a “buy” rating and upped their price target for the company from $2.00 to $35.00 in a research report on Friday, September 20th.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.